Home » Newsletters » BioWorld Science

BioWorld Science

May 27, 2020

View Archived Issues

Early roots of ALS visible in teeth

Can N-BPs become MVP again?

IL-10 upregulation with AD-110 improves cognition and stroke deficits in animal studies

FDA clears IND application for phase I study of Q-702

FDA gives accelerated response to proposed TSC COVID-19 clinical program

Sorrento receives FDA clearance to initiate a phase I study of STI-6129 in amyloidosis

ATx-201 found safe and able to improve skin barrier function biomarkers in phase II study

LFS-829 significantly reverses the pathological features of colitis in vivo

Surprise suggestion for CAR T neurotoxicity culprit

Gilead identifies new integrin alpha4beta7 antagonists

Atara Biotherapeutics presents phase I data on ATA-188 in patients with progressive MS

Merck & Co. patents IDO-1 inhibitors

New Mcl-1 inhibitors disclosed by Prelude Therapeutics

Dana-Farber Cancer Institute presents new JAK2 inhibitors

GPR139 receptor modulators discovered at BlackThorn Therapeutics

PRIMVAC placental malaria vaccine immunogenic but shows limited cross-reactivity in trial

Topline phase Ib results support further development of DUR-928 in NASH

Phase III Archway study of Port Delivery System with ranibizumab in wet AMD meets primary endpoint

FDA approves Dupixent for moderate to severe atopic dermatitis in children aged 6-11 years

Arena updates progress of etrasimod and other pipeline programs

Innovent begins phase I trial in China with anti-TIGIT antibody IBI-939

New phase I/II trial explores next-generation lytic immunotherapy CyPep-1 in advanced solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...